UNITY will host a conference call and webcast for investors and analysts on Tuesday, October 5 at 8:00 a.m. ET to discuss the most recent UBX1325 clinical data. Dr. Bhisitkul and members of the UNITY senior management team will lead the discussion on the 12-week data results.

UBX1325 is an investigational compound being studied for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy that is not approved for any use in any country. UBX1325 is a potent small-molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival.

A Q&A session will follow the presentation.